CF33 is an Oncolytic Virotherapy

[Nev Black 13]

Imugene is a company listed on the Australian Stock Exchange. (This is not a recommendation to buy shares in this company)

CF33 is an Oncolytic Virotherapy which will be used in a Phase 1 Trial, in Australia, starting next year. CF33 will be trailed on a number of cancers.

Unfortunately, Prostate Cancer was not on the list.  

 

 

04/11/2019   Imugene Receives $4.13 million R&D Tax Incentive

 

https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5dbfcc1869d48f23f8e0a4bd/1572850714901/Imugene+Receives+%244.13+million+R%26D+Tax+Incentive.pdf

 

 

21/10/2019   CF33 Oncolytic Virus Clinical Trial Program Update

 

https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5dac7a22fe152f3a7a9ce236/1571584547049/CF33+Clinical+Development+Plan.pdf

 

(The announcements below are publicly available on the Australian Stock Exchange Announcements page)